Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury

Ying Chao Chou, Yung Heng Hsu, Demei Lee, Jheng Wei Yang, Yi Hsun Yu, Err Cheng Chan, Shih Jung Liu*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

1 Scopus citations


A novel bioresorbable drug-eluting polycaprolactone (PCL) mesh scaffold was developed, utilizing a solvent-cast additive manufacturing technique, to promote therapy of muscle injury. The degradation rate and mechanical properties strength of the PCL mesh were characterized after immersion in a buffer solution for different times. The in vitro release characteristics of vancomycin, ceftazidime, and lidocaine from the prepared mesh were evaluated using a high-performance liquid chromatography (HPLC) assay. In addition, the in vivo efficacy of PCL meshes for the repair of muscle injury was investigated on a rat model with histological examinations. It was found that the additively manufactured PCL meshes degraded by 13% after submission in buffered solution for four months. All PCL meshes with different pore sizes exhibited greater strength than rat muscle and survived through 10,000 cyclic loadings. Furthermore, the meshes could offer a sustained release of antibiotics and analgesics for more than 3 days in vitro. The results of this study suggest that drug-loaded PCL mesh exhibits superior ability to pure PCL mesh in terms of effectively promoting muscle repair in rat models. The histological assay also showed adequate biocompatibility of the resorbable meshes. The additively manufactured biodegradable drug-eluting meshes may be adopted in the future in humans for the therapy of muscle injuries.

Original languageEnglish
Pages (from-to)2595-2606
Number of pages12
JournalACS Biomaterials Science and Engineering
Issue number4
StatePublished - 08 04 2024

Bibliographical note

Publisher Copyright:
© 2024 American Chemical Society.


  • biodegradable meshes
  • drug-eluting scaffolds
  • muscle injury treatment


Dive into the research topics of 'Novel Bioresorbable Drug-Eluting Mesh Scaffold for Therapy of Muscle Injury'. Together they form a unique fingerprint.

Cite this